Resistance of tumor cells to TRAIL-induced apoptosis continues to be an important factor in the failure of clinical trials, which indicates that only when a TRAIL sensitizer is used can cancer therapy containing TRAIL be effective. Here, TNFSF10 is linked to neoplasm.